Data includes seven-year results from monarchE trial and updates on multiple investigational cancer therapies. Eli Lilly and Company (NYSE: LLY) announced today that it will present new data from a broad spectrum of its oncology portfolio at the upcoming European…
Oticara Reports Positive Phase 2 Results for Novel Nasal-Mucosa-Optimized Steroid Cream in Hard-to-Treat Post-Surgical Chronic Rhinosinusitis Oticara, a clinical-stage biopharmaceutical company focused on developing innovative therapies for chronic rhinosinusitis (CRS), has announced encouraging outcomes from its Phase 2 OT-007B clinical…
IDT and Hamilton Partner to Automate NGS Workflows, Accelerating Biomarker and Genomic Discovery Integrated DNA Technologies (IDT), a global leader in genomics solutions, has announced a new strategic partnership with precision laboratory automation pioneer Hamilton (Hamilton Company and Hamilton Bonaduz…
Pulse Biosciences Unveils Promising First-in-Human Feasibility Data for the nPulse™ Cardiac Surgical System at EACTS 2025 Pulse Biosciences, Inc. (Nasdaq: PLSE), a clinical-stage medical technology company pioneering the use of its novel nPulse™ technology based on Nanosecond Pulsed Field Ablation™…
Prilenia and Ferrer Highlight Compelling New Evidence of Pridopidine’s Disease-Modifying Potential in Huntington’s Disease at the 2025 HSG Congress Prilenia Therapeutics B.V. and Ferrer have jointly announced the presentation of five new scientific posters at the 2025 Huntington Study Group…
Novo Nordisk to Acquire Akero Therapeutics to Strengthen MASH Pipeline with Phase 3 FGF21 Analogue Efruxifermin Novo Nordisk, a global healthcare leader in diabetes and obesity treatments, has announced a definitive agreement to acquire Akero Therapeutics, Inc., a publicly traded,…
Eikonizo Therapeutics Highlights Breakthrough Preclinical Findings Demonstrating the Disease-Modifying Potential of Selective HDAC6 Inhibitors in ALS and FTD Eikonizo Therapeutics, a biopharmaceutical company focused on developing disease-modifying therapies for neurodegenerative and cardiorenal diseases, has announced the advance online publication of…
Aarvik Therapeutics Secures Strategic Investment from Laurus Labs in Series Seed 2 Financing Round Aarvik Therapeutics, a pioneering biotechnology company focused on developing next-generation antibody-drug conjugates (ADCs) for cancer therapy, today announced a strategic investment by Laurus Labs, India, as…
Celltrion Showcases Real-World Evidence Supporting Switch from IV to Subcutaneous Infliximab at UEG Week 2025 Celltrion, Inc., a global leader in biopharmaceutical innovation, today highlighted compelling real-world evidence supporting the use of subcutaneous (SC) infliximab for patients with inflammatory bowel…
KalVista Pharmaceuticals Highlights EKTERLY® (Sebetralstat) as a Transformative Oral On-Demand Therapy for Hereditary Angioedema in Europe KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), a clinical-stage biotechnology company focused on developing innovative therapies for hereditary angioedema (HAE) and related disorders, today unveiled compelling…
Sonoma Biotherapeutics Co-Founder Fred Ramsdell Awarded 2025 Nobel Prize in Physiology or Medicine for Pioneering FOXP3 Discovery and Advancing Treg Immunotherapy Sonoma Biotherapeutics, Inc., a leading clinical-stage biotechnology company focused on developing engineered regulatory T cell (Treg) therapies for autoimmune…
Ignota Labs Strengthens Clinical Portfolio Through Acquisition of Kronos’s Development-Stage Assets Ignota Labs, an emerging pioneer in artificial intelligence–driven drug redevelopment, has announced the strategic acquisition of Kronos’s former clinical assets—istisociclib, a cyclin-dependent kinase 9 (CDK9) inhibitor, and entospletinib and…